Novel cardiovascular risk factors in the elderly and their correlation with the Framingham risk score

Journal of Cardiovascular Medicine

Volumn 9, Issue 7, 2008, Pages 683-687

  Halil, Meltem ^a   Yavuz, Bunyamin ^b   Yavuz, Burcu Balam ^a   Cankurtaran, Mustafa ^a   Dede, Didem Sener ^a   Ulger, Zekeriya ^a   Barak, Anl ^a   Karabulut, Erdem ^a   Aytemir, Kudret ^a   Kabakci, Giray ^a   Ariogul, Servet ^a   Oto, Ali ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Kecioren Training and Research Hospital   (Turkey)

Author keywords

Coronary heart disease; Elderly; Ferritin; Framingham risk score; Homocysteine

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FERRITIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; FOLIC ACID BLOOD LEVEL; FRAMINGHAM RISK SCORE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; C-REACTIVE PROTEIN; CORONARY DISEASE; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; HOMOCYSTEINE; HUMANS; LIPOPROTEINS, HDL; MALE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; URIC ACID;

EID: 55249114467     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3282f394a5     Document Type: Article

References (32)

1. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94:20-24.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
3. Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J 1982; 103:1031-1039.
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham Study. Ann Intern Med 1977; 87:393-397.
5. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988; 62:1109-1112.
6. Rutter MK, Meigs JB, Sullivan LM, D'AgostinoRBSr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110:380-385.
7. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 2004; 25:523-530.
8. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86:803-811.
9. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89:102-108.
10. Berge LN, Bonaa KH, Nordoy A. Serum ferritin, sex hormones, and cardiovascular risk factors in healthy women. Arterioscler Thromb 1994; 14:857-861.
11. Craig WY, Poulin SE, Palomaki GE, Neveux LM, Ritchie RF, Ledue TB. Oxidation-related analytes and lipid and lipoprotein concentrations in healthy subjects. Arterioscler Thromb Vasc Biol 1995; 15:733-739.
12. www.nhlbi.nih.gov/about/framingham/riskabs.htm
13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 01-3670; May 2001.
14. Hardin J, Hilbe J. Generalized Linear Models and Extensions. Texas: Stata Press; 2001.
15. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron store in normal subjects. Am J Clin Nutr 1974; 27:681-687.
16. Kaltwasser JP, Werner E. Diagnosis and clinical evaluation of iron overload. Baillieres Clinical Haematology 1989; 2:363-385.
17. Lauffer RB. Iron stores and the international variation in mortality from coronary artery disease. Medical Hypotheses 1991; 35:96-102.
18. Pilote L, Joseph L, Belisle P, Robinson K, Van Lente F, Tager IB. Iron stores and coronary artery disease: A clinical application of a method to incorporate measurement error of the exposure in a logistic regression model. J Clin Epidemiol 2000; 53:809-816.
19. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96:2542-2544.
20. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteineas a risk factor for vascular disease. Probable benefits of increasing folicacid intakes. JAMA 1995; 274:1049- 1057.
21. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236.
22. Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomized, placebo-controlled trial. Lancet 2000; 355:517-522.
23. Potena L, Grigioni F, Magnani G, Sorbello S, Sassi S, Poci MG, et al. Folate supplementation after heart transplantation: effects on homocysteine plasma levels and allograft vascular disease. Clin Nutr 2002; 21:245-248.
24. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, et al. Effect of folic acid on endothelium-dependent vasodilation and nitric oxid-derived products in hyperhomocysteinemiac subjects. Am J Med 2001; 110:536-542.
25. Woo KS, Chook P, Chan LL, Cheung AS, Fung WH, Qiao M, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am J Med 2002; 112:535-539.
26. Klein R, Klein BE, Cornoni J, Maready J, Cassel JC, Tyroler HA. Serum uric acid, Georgia. Arch Intern Med 1973; 132:401-410.
27. Bengtsson C, Lapidus L, Stendahal C, Waldenström J. Hyperuricemia and risk of cardiovascular disease and overall death. Acta Med Scand 1988; 224:549-555.
28. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women. J Clin Epidemiol 1989; 42:257-267.
29. Burack RC, Keller JB, Higgins MW. Cardiovascular risk factors and obesity. J Chronic Dis 1985; 38:865-872.
30. Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005; 45:1003-1012.
31. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, et al., Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 2004; 164:969-976.
32. Astor BC, Arnett DK, BrownA,Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2004; 43:836-845.